Skip to main navigation

Skip to Content

Menu

About Cerevel
Our Programs
Our Science
Investor & Media
Careers
- Working at Cerevel Therapeutics
- Open positions
Contact Us

News & Announcements

News & Announcements

Year

Nov 29, 2023

Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease

Nov 08, 2023

Cerevel Therapeutics to Present at Upcoming Investor Conferences

Nov 01, 2023

Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Oct 13, 2023

Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023

Oct 11, 2023

Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock

Oct 11, 2023

Cerevel Therapeutics Announces Proposed Public Offering of Common Stock

Aug 29, 2023

Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Aug 02, 2023

Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Jul 05, 2023

Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023

Jun 15, 2023

Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 20

Print

RSS Feeds

Email Alerts

Investor Contact

Search

Cerevel

About CerevelAbout Cerevel
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- CVL-865
- CVL-231
- CVL-936
Our ScienceOur Science
- Our scientific strategy
- Our pipeline
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- Darigabat
- CVL-231
- CVL-936
Investors & MediaInvestors & Media
- Overview
- News & Events
- Stock
- Financials
- Governance
- Resources
CareersCareers
- Working at Cerevel Therapeutics
- Open Positions
Contact Us

Facebook
Twitter
LinkedIn
YouTube

Cerevel

Terms of Use
Privacy Policy
FCOI
Early Access Program (EAP) Policy

© 2023 Cerevel Therapeutics

CEREVEL and the CEREVEL logo are trademarks of

Cerevel Therapeutics. All Rights Reserved.